Bayer AG and Teva Pharmaceuticals USA Inc. Nov. 21 ended their patent fight over whether Teva’s application to sell a generic copy of Bayer’s erectile dysfunction drug Levitra (vardenafil hydrochloride tablets) infringed two patents on the drug (Bayer Schering Pharma AG v. Teva Pharmaceuticals USA Inc.).
Chief Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware entered a consent judgment ending the patent battle initiated in 2009 (7 PLIR 798, 7/10/09) after the parties reached a settlement in the litigation. Sleet entered judgment in favor of Bayer and against Teva on ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.